Market cap
$248 Mln
Revenue (TTM)
$53 Mln
P/E Ratio
--
P/B Ratio
14.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-208 Mln
-
ROE
-8.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.9
-
Debt to Equity
-10.7
-
Book Value
$--
-
EPS
$-1.7
-
Face value
--
-
Shares outstanding
168,364,992
10 Years Aggregate
CFO
$-1,036.63 Mln
EBITDA
$-1,163.97 Mln
Net Profit
$-1,212.83 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Epizyme (EPZM)
| -41.2 | 0.0 | 212.8 | -73.2 | -49.6 | -35.4 | -- |
|
BSE Sensex*
| -10.4 | -1.0 | -7.8 | -7.7 | 6.7 | 8.3 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Epizyme (EPZM)
| -77.0 | -55.9 | 299.4 | -50.7 | 3.7 | -24.5 | -15.1 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Epizyme (EPZM)
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of... metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc.. Read more
-
Pres, CEO, Principal Financial Officer & Director
Mr. Grant C. Bogle
-
Pres, CEO, Principal Financial Officer & Director
Mr. Grant C. Bogle
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Epizyme (EPZM)
What is the current share price of Epizyme Inc (EPZM) Today?
The share price of Epizyme Inc (EPZM) is $1.47 (NASDAQ) as of 12-Aug-2022 09:30 EDT. Epizyme Inc (EPZM) has given a return of -49.63% in the last 3 years.
What is the current PB & PE ratio of Epizyme Inc (EPZM)?
Since, TTM earnings of Epizyme Inc (EPZM) is negative, P/E ratio is not available.
The P/B ratio of Epizyme Inc (EPZM) is 14.84 times as on 12-Aug-2022, a 186 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-1.03
|
-12.45
|
|
2020
|
-4.73
|
5.93
|
|
2019
|
-13.00
|
6.69
|
|
2018
|
-3.59
|
1.90
|
|
2017
|
-5.70
|
3.25
|
What is the 52 Week High and Low of Epizyme Inc (EPZM)?
The 52-week high and low of Epizyme Inc (EPZM) are Rs -- and Rs -- as of 27-May-2026.
What is the market cap of Epizyme Inc (EPZM)?
Epizyme Inc (EPZM) has a market capitalisation of $ 248 Mln as on 12-Aug-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Epizyme Inc (EPZM)?
Before investing in Epizyme Inc (EPZM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.